Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568–81.
Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interf Cytokine Res. 2015;35(1):1–16.
Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35(1):1–16.
Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17(5):325–37.
Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984–1010.
Fabre JAS, Giustinniani J, Garbar C, Merrouche Y, Antonicelli F, Bensussan A. The Interleukin-17 Family of Cytokines in Breast Cancer. Int J Mol Sci. 2018;19(12):3880. https://www.mdpi.com/1422-0067/19/12/3880.
Somerset W, Stout SC, Miller AH, Musselman D. Breast cancer and depression. Oncology. 2004;18(8):1021–34.
Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43(6):1518–28.
Hüfner K, Oberguggenberger A, Kohl C, Geisler S, Gamper E, Meraner V, Egeter J, Hubalek M, Beer B, Fuchs D. Levels in neurotransmitter precursor amino acids correlate with mental health in patients with breast cancer. Psychoneuroendocrinology. 2015;60:28–38.
Saad S, Dunn LB, Koetters T, Dhruva A, Langford DJ, Merriman JD, West C, Paul SM, Cooper B, Cataldo J. Cytokine gene variations associated with subsyndromal depressive symptoms in patients with breast cancer. Eur J Oncol Nurs. 2014;18(4):397–404.
Kim J-M, Stewart R, Kim S-Y, Kang H-J, Jang J-E, Kim S-W, Shin I-S, Park M-H, Yoon J-H, Park S-W. A one year longitudinal study of cytokine genes and depression in breast cancer. J Affect Disord. 2013;148(1):57–65.
Lyon DE, Schubert C, Taylor AG. Pilot study of cranial stimulation for symptom management in breast cancer. Oncol Nurs Forum. 2010;37(4):476.
Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, Lüftner D. Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012;136(3):789–94.
Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(6):1242–7.
Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatr. 2001;158(8):1252–7.
Sepah SC, Bower JE. Positive affect and inflammation during radiation treatment for breast and prostate cancer. Brain Behav Immun. 2009;23(8):1068–72.
Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O’Dwyer A-M, Harkin A, Kennedy MJ, Connor TJ. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun. 2013;34:108–19.
Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011;29(26):3517–22.
Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol. 2005;69(1):85–96.
Kim S-Y, Kim J-M, Kim S-W, Shin I-S, Park M-H, Yoon J-H, Choi C, Yoon J-S. Associations between plasma cytokines and depressive mood in patients with breast cancer. Int J Psychiatry Med. 2012;43(1):1–17.
Blomberg BB, Alvarez JP, Diaz A, Romero MG, Lechner SC, Carver CS, Holley H, Antoni MH. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J Psychosom Res. 2009;67(5):369–76.
Baumgartner R, Forteza MJ, Ketelhuth DFJ. The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis. Cytokine. 2017;122:154148.
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10.
Chagas MH, Tumas V, Rodrigues GR, Machado-de-Sousa JP, Filho AS, Hallak JE, Crippa JA. Validation and internal consistency of patient health Questionnaire-9 for major depression in Parkinson's disease. Age Ageing. 2013;42(5):645–9.
Elomaa A-P, Niskanen L, Herzig K-H, Viinamäki H, Hintikka J, Koivumaa-Honkanen H, Honkalampi K, Valkonen-Korhonen M, Harvima IT, Lehto SM. Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry. 2012;12(1):2.
KÖNIG A, VILSMAIER T, RACK B, FRIESE K, JANNI W, JESCHKE U, ANDERGASSEN U, TRAPP E, JÜCKSTOCK J, JÄGER B, et al. Determination of Interleukin-4, −5, −6, −8 and −13 in serum of patients with breast Cancer before treatment and its correlation to circulating tumor cells. Anticancer Res. 2016;36(6):3123–30.
Lee E-J, Lee S-J, Kim S, Cho S-C, Choi YH, Kim W-J, Moon S-K. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal. 2013;25(10):2025–38.
Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361–9.
AlHossiny M, Luo L, Frazier WR, Steiner N, Gusev Y, Kallakury B, Glasgow E, Creswell K, Madhavan S, Kumar R, et al. Ly6E/K signaling to TGFβ promotes breast Cancer progression, immune escape, and drug resistance. Cancer Res. 2016;76(11):3376–86.
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–e28.
Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5(3):194–203.
Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol. 2003;13(6):449–59.
Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26.
McCarty R. The alarm phase and the general adaptation syndrome: two aspects of Selye’s inconsistent legacy. In: Stress: Concepts, Cognition, Emotion, and Behavior. Boston: Elsevier; 2016. p. 13–9.
Tian R, Hou G, Li D, Yuan T-F. A possible change process of inflammatory cytokines in the prolonged chronic stress and its ultimate implications for health. Sci World J. 2014;2014:780616.
Kim Y-K, Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatrica. 2003;15(3):148–55.
Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation. 2009;16(5):300–17.
You Z, Luo C, Zhang W, Chen Y, He J, Zhao Q, Zuo R, Wu Y. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res. 2011;225(1):135–41.
Ratnayake U, Quinn T, Walker D, Dickinson H. Cytokines and the neurodevelopmental basis of mental illness. Front Neurosci. 2013;7:180.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.
Wang X-M, Walitt B, Saligan L, Tiwari AFY, Cheung CW, Zhang Z-J. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015;72(1):86–96.
Bansal Y, Kuhad A. Mitochondrial dysfunction in depression. Curr Neuropharmacol. 2016;14(6):610–8.
Matsumoto K, Nakajima T, Sakai H, Kato S, Sagara A, Arakawa K, Tashima K, Narita M, Horie S. Increased expression of 5-HT3 and NK1 receptors in 5-fluorouracil-induced Mucositis in mouse jejunum. Dig Dis Sci. 2013;58(12):3440–51.
Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol (Oxf). 2010;24(4):455–69.
Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229.